CDKN2A and central nervous system cancer: It has also been shown that in gliomas, hypermutation and acquired CDKN2A deletion are closely associated with an increase in tumor cells at the time of recurrence of this tumor, and that its changes reflect the active growth state in which the tumor cells are in31.